Law360, Fort Wayne (April 20, 2017, 5:54 PM EDT) -- Momenta and Sandoz on Thursday asked a Massachusetts federal judge to toss a revived antitrust suit by Amphastar claiming they stifled competition for generic anticoagulant enoxaparin, saying there have been no barriers to selling the drug.
Amphastar Pharmaceuticals Inc. alleges that Momenta Pharmaceuticals Inc. tricked the U.S. Pharmacopeial Convention into adopting a method to test enoxaparin without disclosing that it held a patent that covered the test, but Momenta and Sandoz Inc. said in a motion to dismiss that the method was not mandatory.
The U.S....
Momenta, Sandoz Again Try To Nix Amphastar's Antitrust Suit
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
